Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Acute Myeloid Leukemia Therapeutics Market Growth Opportunities, Major Competitors and Porter Analysis

The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

Acute Lymphoblastic Leukemia (ALL) Therapeutics

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/acute-myeloid-leukemia-therapeutics-market/report-sample

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market

The acute myeloid leukemia therapeutics market was the largest market in the U.S. region of North America in year 2016, and it is expected to remain the largest during the forecast period due to large number of research and development activities.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

Tags: Acute Myeloid, Acute Myeloid Leukemia Therapeutics Market, Acute Myeloid Leukemia Therapeutics Market Analysis, Acute Myeloid Leukemia Therapeutics Market Demand, Acute Myeloid Leukemia Therapeutics Market Share, Acute Myeloid Leukemia Therapeutics Market Size

See Campaign: http://www.psmarketresearch.com/market-analysis/acute-myeloid-leukemia-therapeutics-market
Contact Information:
Contact: P&S Intelligence 347, 5th Ave. #1402 New York City, NY - 10016 Toll-free: +18887787886 (USA/Canada) Email: [email protected] Web: https://www.psmarketresearch.com

Tags:
iCrowdNewswire, Research Newswire, Press Release, North America, South America, United States, Latin America, English

image


This post first appeared on ICrowdNewswire -, please read the originial post: here

Share the post

Acute Myeloid Leukemia Therapeutics Market Growth Opportunities, Major Competitors and Porter Analysis

×

Subscribe to Icrowdnewswire -

Get updates delivered right to your inbox!

Thank you for your subscription

×